New hope for advanced tumors? early trial of SKB410 begins
NCT ID NCT05906537
First seen May 18, 2026 · Last updated Jun 15, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug called SKB410 in about 54 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any early signs that the drug can control tumor growth. Participants receive multiple doses of the drug, and doctors monitor side effects and tumor response closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.